...
首页> 外文期刊>Toxicology in vitro: an international journal published in association with BIBRA >In vitro detection of contact allergens: development of an optimized protocol using human peripheral blood monocyte-derived dendritic cells.
【24h】

In vitro detection of contact allergens: development of an optimized protocol using human peripheral blood monocyte-derived dendritic cells.

机译:接触性过敏原的体外检测:使用人外周血单核细胞衍生的树突状细胞开发优化方案。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Allergic contact dermatitis is a delayed T-cell mediated allergic response associated with relevant social and economic impacts. Animal experiments (e.g. the local lymph node assay) are still supplying most of the data used to assess the sensitization potential of new chemicals. However, the 7th amendment to the EU Cosmetic Directive will introduce a testing ban for cosmetic ingredients after 2013. In vitro alternative methods are thus being actively developed. Although promising results have been obtained with cell lines, their reduced functionality and inherent genomic instability led us to reinvestigate the use of peripheral blood monocyte-derived dendritic cells (PBMDCs) for the establishment of a reliable in vitro sensitization test. To solve the issues associated with the use of primary cells, the culture and exposure conditions (cytokine concentrations, incubation time, readout, pooled vs. single donors and cytotoxicity) were re-assessed and optimized. Here we propose a stable and reproducible protocol based on PBMDCs. This should allow a wider acceptance of PBMDCs as a reliable test system for the detection of human skin sensitizers and the inclusion of this protocol in an integrated testing strategy.
机译:过敏性接触性皮炎是与相关的社会和经济影响相关的延迟性T细胞介导的过敏反应。动物实验(例如局部淋巴结测定)仍在提供大多数用于评估新化学物质潜在致敏性的数据。但是,《欧盟化妆品指令》第7条修正案将在2013年之后引入对化妆品成分的测试禁令。因此,正在积极开发体外替代方法。尽管细胞系已获得了令人鼓舞的结果,但它们降低的功能和固有的基因组不稳定性使我们重新研究了外周血单核细胞衍生的树突状细胞(PBMDC)的使用,以建立可靠的体外致敏性测试。为了解决与使用原代细胞相关的问题,重新评估和优化了培养和暴露条件(细胞因子浓度,孵育时间,读数,合并供体与单供体以及细胞毒性)。在这里,我们提出了一种基于PBMDC的稳定且可重现的协议。这应该允许PBMDC作为一种可靠的测试系统被更广泛地接受,用于检测人类皮肤敏化剂,并且可以将该协议包含在集成测试策略中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号